Prot# 1200.28: A Randomized, Open-Label Phase II Study of BIBW 2992 versus Cetuximab (Erbitux) in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after Failure of Platinum-Containing Therapy with a Cross-Over Period for

  • Agulnik, Mark (PD/PI)

Project: Research project

Project Details

Effective start/end date12/11/077/1/13


  • Boehringer Ingelheim Pharmaceuticals, Inc. (1200.28)